摘要
抗体偶联药物(antibody-drug conjugates, ADC)由单克隆抗体、连接子和细胞毒药物3部分共价偶联组成,是一类新型的肿瘤治疗药物。ADC药物创新的分子设计和作用机制兼具传统化疗药物对肿瘤细胞的强大杀伤作用以及抗体药物的精准靶向性,近年来越来越受到关注。同时在ADC药物肿瘤治疗中,对可能出现的血液系统、心脏、肺、肝、眼毒性等药物不良反应进行必要的管理不容忽视。截至2022年8月,在我国已有5种ADC药物获批上市,随着ADC药物的广泛应用,建立多学科联合的用药安全性管理体系,有助于把握ADC药物相关不良反应最佳的治疗时机并及时制定最优处置方案。为此中国药学会医院药学专业委员会和中国抗癌协会肿瘤临床化疗专业委员会,根据我国ADC药物不良反应管理现状,结合国际最新理论和循证医学证据,组织相关专家讨论并联合制定了ADC药物不良反应跨学科管理中国专家共识。
Antibody-drug conjugate(ADC) is a new type of tumor therapeutic drug, which is composed of monoclonal antibody, linker, and cytotoxic drug. The innovative molecular design and mechanism of action of ADC drugs, which combines the strong killing effect of traditional chemotherapy drugs on tumor cells with the precise targeting of antibody drugs, have attracted more and more attention in recent years. However, the management of adverse drug reactions such as hematotoxicity, cardiotoxicity, pulmonary toxicity, hepatotoxicity, and ocular toxicity should not be ignored during cancer treatment with ADC drugs. As of August 2022, a total of five ADC drugs have been approved for marketing in China. With the wide application of ADC drugs, the establishment of a multidisciplinary drug safety management system will help to grasp the optimal treatment opportunity for ADC drug-related adverse reactions and formulate the optimal treatment plans in time. Therefore, the Hospital Pharmacy Committee of Chinese Pharmaceutical Association and the Tumor Clinical Chemotherapy Committee of Chinese Anticancer Association have organized relevant experts to discuss and jointly formulate the consensus of Chinese experts on the interdisciplinary management of ADC-related adverse reactions based on the current situation of management in China and the latest international theories and experiences.
出处
《中国医院药学杂志》
CAS
北大核心
2023年第1期1-10,60,共11页
Chinese Journal of Hospital Pharmacy
关键词
抗体偶联药物
不良反应
多学科
专家共识
antibody-drug conjugate
adverse drug reactions
multidisciplinary
expert consensus
